ClinicalTrials.gg
CompletedNCT03967951Updated Sep 23, 2026

CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms

An observational study in Pancreatic Neuroendocrine Tumor, sponsored by Francesco De Cobelli. Completed at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Francesco De Cobelli · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
70
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Adenoma, Islet Cell with a site in Italy — 3 open to participants now, 6 under way, 1 of them phase 3. Adenoma, Islet Cell · Italy.

Started
2019
the only one that year
Observational
6 of 11
1 open now
Registered
4th of 11
by date
Lead sponsor
1 of 11
Francesco De Cobelli

Among the 11 studies in Adenoma, Islet Cell with a site in Italy, this one is the only one that started in 2019, is one of 6 observational ones, and was the 4th registered.

Adenoma, Islet Cell

113 studies on the registry are indexed under Adenoma, Islet Cell; 30 are open to participants now.

Browse Adenoma, Islet Cell studies →

Open to participants now

3 of the 11 studies in Adenoma, Islet Cell with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 24 Adenoma, Islet Cell studies recruiting now, 17 (71%) set no upper age limit and 2 (8%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Adenoma, Islet Cell with a site in Italy, or all of them as a file.
02

Study summary

The aim of this study is to quantify inter-observer variability in delineating pancreatic neuroendocrine neoplasm (PanNEN) on Computerized Tomography (CT) images and its impact on radiomic features (RF), subsequently to this determination, to use CT texture analysis to predict, histological characteristics of PanNEN on CT scans.

Read the detailed description

CT imaging is the most widely used modality for studying radiomic features due to its ability to assess tissue density, shape, texture and size before, during and after therapy. To the best of the investigator's knowledge, the impact of inter-observer delineation variability on the reliability of CT RF for PanNEN patients, including Hounsfield unit (HU) values-, shape-, and texture-based features, has not yet been assessed. One this has been determined, an additional evaluation will be conducted to correlate the morphologically observed images with their histopathological characteristics.

The ultimate potential objective of this research is to identify and predict characteristics of aggressiveness of PanNEN in CT scans.

03

Conditions studied

  • Pancreatic Neuroendocrine Tumor

Browse trials for

Keywords

  • Radiomics
  • Pancretic neuroendocrine neoplasms (panNEN)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Monocentric, retrospective, observational study. Subjects who fulfill the inclusion criteria will be randomly chosen from our Institutional data-base. Thirty patients will be used to evaluate inter-observer variability and forty patients will be used to evaluate histological characteristics on CT-scans with and without contrast agent).

Imaged based and clinical variables will be used to construct an overall status of the patient.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 18 years of age
  • pancreatic neuroendocrine neoplasm with intervention and
  • availability of pre-operatory CT scan with or without IV contrast agent- inInstitution from 2009-2017

Exclusion criteria

Exclusion Criteria:

  • pregnant women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
70 participants (actual)
Patient registry
No

Interventions

  • OtherCT radiomic feature evaluation

    Radiomic features will be calculated and extracted from all contrast and non-contrast CT-scans. First order features will be evaluated and high order features will be grouped in parent matrices. Parent matrices of second and third order will be chosen and evaluated. In the second part, based on the results of inter-correlation of the operator analysis, the most significant radiomic features will be chosen. Morphological and histopathological features will be evaluated will be. Histopathology will be performed on a biopsy specimen; percentage of Ki67 and grading will be evaluated.

06

What researchers measure

Primary outcomes

  1. Interobserver variability in delineating panNENs on CT

    Asses inter-observer variability on CT- scans (with contrast alone)

    Time frame: 6 months

Secondary outcomes

  1. Use CT texture analysis to predict, histological characteristics of PanNEN on CT scans

    Evaluate histological characteristics on CT-scans with and without contrast agent in a group of subjects

    Time frame: 6 months

07

Study locations

2 sites
  • Deaprtment of Radiology, IRCCS Ospadale San Raffaele
    Milan, 20132, Italy
  • IRCCS Ospedale San Raffaele
    Milan, 20153, Italy
08

References and documents

Publications

  • Belli ML, Mori M, Broggi S, Cattaneo GM, Bettinardi V, Dell'Oca I, Fallanca F, Passoni P, Vanoli EG, Calandrino R, Di Muzio N, Picchio M, Fiorino C. Quantifying the robustness of [18F]FDG-PET/CT radiomic features with respect to tumor delineation in head and neck and pancreatic cancer patients. Phys Med. 2018 May;49:105-111. doi: 10.1016/j.ejmp.2018.05.013. Epub 2018 May 23. PubMed 29866335 ↗
  • Benedetti G, Mori M, Panzeri MM, Barbera M, Palumbo D, Sini C, Muffatti F, Andreasi V, Steidler S, Doglioni C, Partelli S, Manzoni M, Falconi M, Fiorino C, De Cobelli F. CT-derived radiomic features to discriminate histologic characteristics of pancreatic neuroendocrine tumors. Radiol Med. 2021 Jun;126(6):745-760. doi: 10.1007/s11547-021-01333-z. Epub 2021 Feb 1. PubMed 33523367 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in May 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2019
First posted
May 30, 2019
StartActual
Mar 23, 2019
Primary completionActual
May 6, 2019
CompletionActual
May 6, 2019
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03967951
Lead sponsor
Francesco De Cobelli
Responsible party
Francesco De Cobelli (Professor of Radiology, Head of Clinical and Experimental Radiology, IRCCS San Raffaele) — Sponsor-investigator
First posted
May 30, 2019
Start date
Mar 23, 2019
Primary completion
May 6, 2019
Completion
May 6, 2019
Last update
Sep 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion